Abstract: Sclerodermatous graft-versus-host disease (sGVHD) is a rare, late complication of hematopoietic cell transplantation. Classified as a variant of chronic graft-versus-host disease, sGVHD is thought to be predominantly an immune-mediated response characterized by aberrant T-cell function and dysregulation of tyrosine kinase cascades. Recently, the profibrotic cytokine transforming growth factor B and stimulatory autoantibodies against the platelet-derived growth factor receptor have been implicated in the pathogenesis of sGVHD. Treatment of sGVHD remains disappointing and largely limited by systemic side effects. Imatinib mesylate is a small molecule tyrosine kinase inhibitor that has ...
A Case of Sclerodermatous Graft-versus-Host Disease Responsive to Imatinib Therapy is a post from: Skincare
A Case of Sclerodermatous Graft-versus-Host Disease Responsive to Imatinib Therapy via BuzzBlazer.com
No comments:
Post a Comment